{
    "clinical_study": {
        "@rank": "122716", 
        "arm_group": [
            {
                "arm_group_label": "Prednisolone", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients who will receive prednisolone medication (2 mg/kg/day ) for 16 weeks"
            }, 
            {
                "arm_group_label": "Propranolol", 
                "arm_group_type": "Experimental", 
                "description": "Patients who will receive propranolol medication 2 mg/kg/day for 16 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the safety and efficiency of Propranolol as an\n      initial treatment for pediatric hemangioma."
        }, 
        "brief_title": "The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Hemangioma", 
        "condition_browse": {
            "mesh_term": "Hemangioma"
        }, 
        "detailed_description": {
            "textblock": "-  Randomized (A group : propranolol, B group : prednisolone)\n\n        -  A group : 3 days admission and medication for 16 weeks\n\n        -  B group : medication for 16 weeks without admission\n\n        -  Hemangioma volume comparison by using MRI\n\n        -  other measurement and drug adverse reaction monitoring"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Hemangioma patient ( 0 ~ 9 months old)\n\n          -  No treatment before\n\n          -  10 ~ 20 % volume increase in 2 ~ 4 weeks\n\n          -  Hemangioma that caused organ function\n\n          -  Hemangioma that will cause aesthetic problem\n\n        Exclusion Criteria:\n\n          -  Cardiovascular disease (impossible to use propranolol)\n\n          -  Drug adverse reaction or allergy history (propranolol, steroid)\n\n          -  Bradycardia, Atrioventricular block, atrial block\n\n          -  Cardiogenic Shock\n\n          -  Right heart failure (pulmonary hypertension)\n\n          -  Congestive heart failure\n\n          -  Hypotension\n\n          -  Peripheral nerve disease (moderate)\n\n          -  Angina\n\n          -  Hormone deficiency patient\n\n          -  Pulmonary disease (asthma)\n\n          -  diabetic ketoacidosis\n\n          -  laser treatment history"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "9 Months", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "58", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01908972", 
            "org_study_id": "12172-MM-231"
        }, 
        "intervention": [
            {
                "arm_group_label": "Prednisolone", 
                "description": "2mg/kg/day for 16weeks", 
                "intervention_name": "Prednisolone", 
                "intervention_type": "Drug", 
                "other_name": "steroid"
            }, 
            {
                "arm_group_label": "Propranolol", 
                "description": "2mg/kg/day for 16weeks", 
                "intervention_name": "Propranolol", 
                "intervention_type": "Drug", 
                "other_name": "beta-blocker"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Propranolol", 
                "Methylprednisolone acetate", 
                "Prednisolone acetate", 
                "Prednisolone", 
                "Methylprednisolone", 
                "Methylprednisolone Hemisuccinate", 
                "Prednisolone hemisuccinate", 
                "Prednisolone phosphate"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Hemangioma", 
            "Propranolol", 
            "prednisolone", 
            "steroid"
        ], 
        "lastchanged_date": "January 6, 2014", 
        "location": {
            "contact": {
                "email": "psthchoi@snu.ac.kr", 
                "last_name": "Tae Hyun Choi, MD, Ph D", 
                "phone": "82-2-2072-1978"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "110-744"
                }, 
                "name": "Seould National University Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Safety and Efficiency of Propranolol as an Initial Treatment for Pediatric Hemangioma", 
        "overall_contact": {
            "email": "psthchoi@snu.ac.kr", 
            "last_name": "Tae Hyun Choi, MD, Ph D", 
            "phone": "82-2-2072-1978"
        }, 
        "overall_contact_backup": {
            "email": "psdrj2h@gmail.com", 
            "last_name": "Jae Hoon Jeong, MD", 
            "phone": "82-31-787-7225"
        }, 
        "overall_official": [
            {
                "affiliation": "Seoul National University Hospital", 
                "last_name": "Kyung-Duk Park, MD, Ph D", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Seoul National University Hospital", 
                "last_name": "Tae Hyun Choi, MD, Ph D", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "We compared hemangioma volume measured by MRI or SONO, before and 16 weeks after medications.", 
            "measure": "Hemangioma volume measured by MRI or SONO", 
            "safety_issue": "No", 
            "time_frame": "After 16weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01908972"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Measure the horizontal and vertical size (2-dimension)", 
                "measure": "Size changes from baseline", 
                "safety_issue": "No", 
                "time_frame": "After 16 weeks"
            }, 
            {
                "description": "Heart rate fall to <70% of acceptable age related minimum post-dose with child awake", 
                "measure": "Heart rate change from Baseline at 16 weeks", 
                "safety_issue": "Yes", 
                "time_frame": "up to 16weeks"
            }, 
            {
                "description": "Red/Purple/Blue/Gray/Apricot", 
                "measure": "Change from Baseline in color", 
                "safety_issue": "No", 
                "time_frame": "After 16 weeks"
            }, 
            {
                "description": "Measure the horizontal and vertical size (2-dimension)", 
                "measure": "Changes in Size of Ulceration", 
                "safety_issue": "No", 
                "time_frame": "After 16 weeks"
            }, 
            {
                "description": "Yes/No", 
                "measure": "Whether or not Re-epithelized in 16weeks", 
                "safety_issue": "No", 
                "time_frame": "After 16 weeks"
            }, 
            {
                "description": "The time when hemangioma stop growing within 16 weeks", 
                "measure": "Stop time of proliferation", 
                "safety_issue": "No", 
                "time_frame": "After 16 weeks"
            }, 
            {
                "description": "The time when hemangioma decreased to 75% of baseline size", 
                "measure": "Time of regression", 
                "safety_issue": "No", 
                "time_frame": "Within 16 weeks"
            }, 
            {
                "description": "Check the number of having drugs and skip time.", 
                "measure": "Drug compliance within 16 weeks", 
                "safety_issue": "No", 
                "time_frame": "After 16 weeks"
            }, 
            {
                "description": "Systolic blood pressure fall of >25% of baseline postdose with child awake", 
                "measure": "Change from Baseline in systolic blood pressure at 16 weeks", 
                "safety_issue": "Yes", 
                "time_frame": "up to 16weeks"
            }, 
            {
                "description": "Check the Glucose level whether to fall (to <50mg/dl)", 
                "measure": "Changes from baseline in Glucose level at 16 weeks", 
                "safety_issue": "Yes", 
                "time_frame": "up to 16weeks"
            }, 
            {
                "description": "Yes/No", 
                "measure": "Whether the facial edema occurs within 16 weeks", 
                "safety_issue": "Yes", 
                "time_frame": "up to 16weeks"
            }, 
            {
                "description": "When the subject do not grow in 16 weeks at all.", 
                "measure": "Whether growth retardation occurs within 16 weeks", 
                "safety_issue": "Yes", 
                "time_frame": "up to 16weeks"
            }, 
            {
                "description": "Yes/No", 
                "measure": "Whether the Gastroesophageal reflux occurs within 16 weeks", 
                "safety_issue": "Yes", 
                "time_frame": "up to 16weeks"
            }, 
            {
                "description": "All symptoms associated adverse drug reaction will be checked", 
                "measure": "Number of Participants with Adverse drug reaction", 
                "safety_issue": "Yes", 
                "time_frame": "up to 16weeks"
            }
        ], 
        "source": "Seoul National University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}